Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

MK-3102

- PMLiVE

Merck and Sun Pharma part company on branded generics

Will continue partnership on diabetes and inflammatory disorder projects

- PMLiVE

Tresiba safer than insulin glargine, says Novo Nordisk

Trial compares its basal insulin with Sanofi's Lantus

- PMLiVE

Merck & Co’s oral hepatitis C therapy approved in US

Fixed-dose combination Zepatier wins a licence from the FDA

- PMLiVE

Germany’s Merck triumphs in court battle with US namesake

English court rules Merck & Co breached the firms' naming agreement

Roche Basel Switzerland

Roche prepares to file atezolizumab for bladder cancer

Imminent submission to the FDA after additional positive phase II trial results

- PMLiVE

Keytruda bounces back in rivalry with Opdivo

First drug in its class to secure FDA approval as a first-line therapy for malignant melanoma

Eli Lilly HQ

Lilly’s Lantus ‘follow-on’ approved in the US

Basaglar is first insulin product to be licensed via the FDA's truncated 505(b)(2) pathway

- PMLiVE

MSD appoints Jessica Fine as UK external affairs director

She joins the UK pharma company from Lexington Health

- PMLiVE

Merck finally bags FDA approval for Bridion

Follows three unsuccessful attempts to gain a US licence for the drug

- PMLiVE

FDA panel rejects cardiovascular outcomes claim for Vytorin

Merck & Co fail to convince regulator's advisors

- PMLiVE

Novo Nordisk will work with IBM on diabetes care

Development of digital platform to help diabetics and their doctors manage their illness

Projects selected for MSD-backed digital accelerator

Disease-specific mobile apps among those winning support from Velocity Health

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links